Cytokinetics ceo
WebMar 31, 2024 · The company in the coming months will assess measures needed for the development of its neuromuscular pipeline, Cytokinetics CEO Robert Blum said in a statement. WebNov 10, 2024 · In 2007, I became both President and CEO.” Cytokinetics is a leader in a specific area of biology focused on the discovery, development and commercialization of new medicines that modulate the mechanics of …
Cytokinetics ceo
Did you know?
WebJan 2024 - Mar 20243 years 3 months. San Francisco Bay Area. Accountable for leading Development Operations to ensure timely … WebOct 27, 2024 · Cytokinetics CEO: Why It's OK Not Being An Overnight Success Licensing ALLISON GATLIN 05:02 PM ET 10/27/2024 Nobody will accuse Cytokinetics ( CYTK) …
WebDec 27, 2024 · Cytokinetics has been finding treatments for muscle weakening conditions such as ALS for 20 years. President and CEO … WebApr 12, 2024 · Cytokinetics, Incorporated has a 1 year low of $32.96 and a 1 year high of $55.80. Cytokinetics (NASDAQ:CYTK – Get Rating) last posted its earnings results on Wednesday, March 1st. The ...
WebOct 27, 2024 · Cytokinetics CEO: Why It's OK Not Being An Overnight Success Investors Business Daily Oct. 27, 2024, 05:02 PM Nobody will accuse Cytokinetics (CYTK) of … WebOct 27, 2024 · Nobody will accuse Cytokinetics (CYTK) of being an 'overnight success,' Chief Executive Robert Blum says. But CYTK stock is trading with enthusi...
WebApr 13, 2024 · The projected fair value for Cytokinetics is US$38.04 based on 2 Stage Free Cash Flow to Equity. Cytokinetics' US$34.05 share price indicates it is trading at similar levels as its fair value estimate
WebJul 14, 2024 · Cytokinetics President and CEO, Robert I. Blum, said: “We are pleased to enter into these transactions with RTW and Ji Xing to both accelerate and expand the development of CK-274 in cardiovascular diseases associated with hypercontractility,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. ... simplicity 1651WebMay 5, 2024 · Cytokinetics, Incorporated (NASDAQ:NASDAQ:CYTK) Q1 2024 Earnings Conference Call May 4, 2024 4:30 PM ETCompany ParticipantsDiane Weiser - SVP of … simplicity 1652WebMar 31, 2024 · Cytokinetics drug reldesemtiv has failed a pivotal clinical trial in amyotrophic lateral sclerosis. The small molecule had previously failed in Phase 2, but the biotech believed adjustments could ... raymarine repair service near meWebMar 31, 2024 · Cytokinetics’ ALS research has revolved around “troponin,” a protein involved in muscle movement, with the idea being that activating this protein may help treat the disease. The company’s first attempt at this resulted in an experimental medicine called tirasemtiv, but it was shelved after missing the primary goal of a late-stage study ... simplicity 1650954smWebMar 31, 2024 · The company in the coming months will assess measures needed for the development of its neuromuscular pipeline, Cytokinetics CEO Robert Blum said in a statement. ALS, also known as Lou Gehrig’s disease, breaks down nerve cells in the brain and spinal cord that make muscles work, leading to progressive paralysis and death. raymarine rewardsWebMar 31, 2024 · Cytokinetics Diane Weiser Senior Vice President, Corporate Communications, Investor Relations (415) 290-7757 Source: Cytokinetics, Incorporated … simplicity 1626WebApr 3, 2024 · Despite these results, Cytokinetics drew out some positive signals of efficacy from a post hoc analysis of the data. After consulting with the FDA, the company decided to push through with a Phase III study of reldesemtiv, Robert Blum, president and CEO, Cytokinetics, told BioSpace in an email. raymarine return address